Teva Pharmaceutical Industries Ltd. on Friday announced that the US Food and Drug Administration (FDA) has approved Quartette (levonorgestrel/ethinyl estradiol and ethinyl estradiol) contraceptive tablets.
Quartette has been designed to minimize breakthrough bleeding (BTB) between scheduled periods. The approval boosts Teva’s decision to focus on an innovative range of women's health pharmaceutical products.
George Washington University School of Medicine clinical professor of Obstetrics and Gynecology Dr. James A. Simon said, “Breakthrough bleeding can be experienced with any birth control pill, especially during the first few months, and is one of the reasons a large number of women discontinue extended regimens. The estrogen in Quartette increases at specific points and provides four short light periods a year. Breakthrough bleeding decreases over time, which might help encourage patient adherence.”